Published in Cancer Weekly, June 29th, 2004
"Specific treatments targeted toward oncogenes expressed in cancer cells are currently under development," scientists in France explained. "Patients with urothelial carcinomas showing HER-2/neu (human epidermal growth factor receptor 2) overexpression are candidates for such a specific treatment (trastuzumab). However, to be effective, this therapeutic approach requires an extremely reliable evaluation of HER-2/neu status in tumors."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.